Cabaletta Bio, Inc. (CABA)
CABA Stock Price Chart
Explore Cabaletta Bio, Inc. interactive price chart. Choose custom timeframes to analyze CABA price movements and trends.
CABA Company Profile
Discover essential business fundamentals and corporate details for Cabaletta Bio, Inc. (CABA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Oct 2019
Employees
161.00
Website
https://www.cabalettabio.comCEO
Steven A. Nichtberger
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
CABA Financial Timeline
Browse a chronological timeline of Cabaletta Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.52.
Earnings released on 7 Aug 2025
EPS came in at -$0.73 falling short of the estimated -$0.71 by -2.82%.
Earnings released on 15 May 2025
EPS came in at -$0.71 falling short of the estimated -$0.67 by -5.97%.
Earnings released on 31 Mar 2025
EPS came in at -$0.65 matching the estimated -$0.65, while revenue for the quarter reached $1.64M .
Earnings released on 14 Nov 2024
EPS came in at -$0.62 falling short of the estimated -$0.59 by -5.08%.
Earnings released on 8 Aug 2024
EPS came in at -$0.56 falling short of the estimated -$0.55 by -1.82%.
Earnings released on 15 May 2024
EPS came in at -$0.51 falling short of the estimated -$0.48 by -6.25%.
Earnings released on 21 Mar 2024
EPS came in at -$0.46 falling short of the estimated -$0.39 by -17.95%, while revenue for the quarter reached $4.01M .
Earnings released on 9 Nov 2023
EPS came in at -$0.37 surpassing the estimated -$0.39 by +5.13%.
Earnings released on 10 Aug 2023
EPS came in at -$0.37 surpassing the estimated -$0.47 by +21.28%.
Earnings released on 11 May 2023
EPS came in at -$0.45 surpassing the estimated -$0.48 by +6.25%.
Earnings released on 16 Mar 2023
EPS came in at -$0.52 falling short of the estimated -$0.47 by -10.64%.
Earnings released on 10 Nov 2022
EPS came in at -$0.39 surpassing the estimated -$0.49 by +20.41%.
Earnings released on 11 Aug 2022
EPS came in at -$0.45 surpassing the estimated -$0.52 by +13.46%.
Earnings released on 12 May 2022
EPS came in at -$0.45 surpassing the estimated -$0.64 by +29.69%.
Earnings released on 17 Mar 2022
EPS came in at -$0.49 surpassing the estimated -$0.68 by +27.94%.
Earnings released on 1 Nov 2021
EPS came in at -$0.45 surpassing the estimated -$0.52 by +13.46%.
Earnings released on 5 Aug 2021
EPS came in at -$0.45 surpassing the estimated -$0.51 by +11.76%.
Earnings released on 3 May 2021
EPS came in at -$0.41 surpassing the estimated -$0.49 by +16.33%.
Earnings released on 16 Mar 2021
EPS came in at -$0.40 falling short of the estimated -$0.34 by -17.65%.
Earnings released on 10 Nov 2020
EPS came in at -$0.36 surpassing the estimated -$0.47 by +23.40%.
CABA Stock Performance
Access detailed CABA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.